Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial

Bruce Cree(University of California, San Francisco), Piotr Sokolowski, Guy Laureys(Ghent University Hospital), Mark S. Freedman(University of Ottawa), Radek Ampapa(Hospital Jihlava), Fred Lublin(Icahn School of Medicine at Mount Sinai), Valerie J. Block(University of California, San Francisco), Rana Zabad, Eva Meluzínová, Gary Cutter(Alabama Department of Public Health), Jana Lízrová Preiningerová, Galina Vorobeychik, Radomír Taláb, Gıancarlo Comı(Vita-Salute San Raffaele University), Elias-Hamp Birte, Jens Kühle(University of Basel), Orhan Aktaş(Heinrich Heine University Düsseldorf), Stephen C. Reingold(Clinical Research Associates), Pierre Duquette(Centre Hospitalier de l’Université de Montréal), Daniela Rau, Marta Vachová(Regional Museum in Teplice), Franz Fazekas(Medical University of Graz), Mathias Buttmann(University of Würzburg), Maria Pia Sormani(University of Genoa), Jennifer Graves(University of California San Diego), Douglas L. Arnold(University of Oxford), Roger McKelvey, Gerd Reifschneider, Barbara Willekens, Tobias Derfuß(University of Basel), Jerry S. Wolinsky(The University of Texas Health Science Center at Houston), Paul S. Giacomini(Montreal Neurological Institute and Hospital), Scott D. Newsome(Johns Hopkins University), Ludivine Chamard Witkowski, Virginia Devonshire, Daniel Selchen, Frederick Munschauer, Mark Marriott(University of Ottawa), Robert P. Lisak(Wayne State University), Hans-Peter Hartung(The University of Sydney), Joshua Barton, Frédéric Sedel(Sorbonne Université), Stephen Krieger(Icahn School of Medicine at Mount Sinai), J Girard, Tania Kuempfel(Ludwig-Maximilians-Universität München), Richard Macdonell, Nina De Klippel, Gavin Giovannoni(Queen Mary University of London)
The Lancet Neurology
October 23, 2020
Cited by 104


Related Papers